OGEN - Oragenics announces peer-reviewed positive data publication for nasal COVID shot candidate

Oragenics (NYSE:OGEN) on Tuesday announced peer-reviewed publication of a co-authored article which concluded that its intranasal COVID-19 vaccine candidate warranted further development. The Tampa, Fla.-based biotech's shares rose 3% to $0.31 in early trading. The article was published in Scientific Reports, a Nature journal, and was written by the company and its collaborators at Inspirevax and the National Research Council of Canada's Human Health Therapeutics Research Centre. The article described studies that evaluated a spike protein subunit vaccine formulation, NT-CoV2-1, in mice and hamsters. The authors concluded that the intranasal formulation induced robust antigen-specific IgG and IgA titers in the blood and lungs of mice and was highly efficacious in a hamster challenge model, reducing the viral load below the limit of detection. The antibodies showed strong neutralizing activity in both mice and hamsters, preventing the cellular binding of the viral spike protein.

For further details see:

Oragenics announces peer-reviewed positive data publication for nasal COVID shot candidate